StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) company profile

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.79−0.08 (-0.27%)

Close on Nov 18, 2026Market cap $1.46BP/E –Yield –

About UroGen Pharma

Pharmaceutical Preparations, SIC 2834

UroGen Pharma is a biotechnology company focused on developing and commercializing therapeutic solutions for urothelial and specialty cancers. Utilizing its proprietary reverse-thermal hydrogel technology, RTGel, the company creates sustained-release formulations designed to extend drug exposure in the urinary tract. Its approved commercial products include Jelmyto, developed to ablate tumors non-surgically in adult patients with low-grade upper tract urothelial cancer, and Zusduri, designed for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Additionally, the company advances pipeline candidates such as UGN-103, UGN-104, and UGN-501. Its customer base comprises healthcare professionals, physicians, hospitals, and pharmacies treating cancer patients.

The company operates commercially within the United States, supported by a specialized field team of approximately 150 customer-facing personnel who engage with urology and oncology practitioners, care facilities, and key accounts. In addition to commercializing products nationwide across Medicare, Medicaid, and private commercial health plans, the company conducts multicenter clinical trials globally. The provided excerpt does not disclose the location of the company's corporate headquarters.

Summary of the business section of UroGen Pharma's latest annual report, written by StockData.

Company profile

Company

Legal name
UroGen Pharma Ltd.
Headquarters
Ra'Anana, L3
Address
9 Ha'Ta'Asiya St 4365007
Phone
972 9 770 7601
Website
urogen.com
Employees
291, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
L3
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Florham Park, New Jersey

Stock & identifiers

Ticker
URGN
Exchange
Nasdaq
IPO date
May 5, 2017
Shares outstanding
49M, Jul 28, 2026
Public float
$620.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1668243
CUSIP
M96088105
FIGI
BBG00GFCC613
Share class FIGI
BBG00GFCC622
LEI
549300C0YCX7CG2G5D50
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Chris DegnanChief Financial Officer4,561
Mark SchoenbergChief Medical Officer67,849
Jason Drew SmithGeneral Counsel53,141
Elizabeth A. BarrettChief Executive Officer313,358
James A. Robinson Jr.Director8,000
Daniel George WildmanDirector2,000
Leana WenDirector2,000
Cynthia M. ButittaDirector2,000
Arie BelldegrunDirector408,693
Stuart HoldenDirector2,000

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.31M$11.84M$1.18M$264–
FY2024$4.15M$1.94M$1.23M$120–
FY2023$4.64M$6.32M$1.43M$169–
FY2022$1.87M$1.77M$832.07K$93–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsIncentive payOtherTotalvs. prior year
Elizabeth Barrett
Chief Executive Officer
$855.59K$774.07K$2.12M$516.26K$42.49K$4.31M+4%
Mark Schoenberg
Chief Medical Officer
$369.61K$167.50K$440.40K$180.00K$13.13K$1.17M+33%
Jason Smith
General Counsel and Chief Compliance Officer
$492.01K$198.96K$220.20K$197.92K$89.53K$1.20M-6%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 5, 2017
Offer price
$13.00
Exchange
Nasdaq
First trading day
May 4, 2017
First-day close
$13.98+7.5%
Lock-up ends (est.)
Oct 31, 2017

“The initial public offering price of our ordinary shares is $13.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of January 31, 2026, we had 291 employees worldwide, 251 in the United States and 40 in Israel, many of whom hold advanced degrees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?